Bruna Pellini

This study shows that stromal niches protect lung cancers from ALK inhibitors through multiple mechanisms, and targeting these mechanisms together is more effective than targeting them individually.

This paper identifies CYP3A4 hyperactivation as a tumor-extrinsic resistance mechanism in NSCLC, showing it reduces drug exposure and leads to resistance, and proposes dosing optimization and CYP3A4 inhibition as solutions.

This study shows that combining trastuzumab deruxtecan with sotorasib improves responses in KRASG12C-mutant NSCLC and overcomes resistance, but HER2 expression levels influence treatment effectiveness.